Chimeric antigen receptor (
CAR)
T cell therapy is a novel
therapeutic approach that uses
gene editing techniques and lentiviral transduction to engineer
T cells so that they can effectively kill
tumors. However,
CAR T cell therapy still has some drawbacks many
patients who received
CAR T cell therapy and achieve remission, still had
tumor relapse and
treatment resistance, which may be due to
tumor immune escape and
CAR T cell dysfunction. To overcome
tumor relapse, more researches are being done to optimize
CAR T cell therapy to make it more precise and personalized, including
screening for more specific
tumor antigens, developing novel
CAR T cells, and combinatorial
treatment approaches. In this
review, we
will discuss the mechanisms as well as the progress of
research on overcoming plans. (AU)
